1. Heterogeneity in PD-L1 expression between primary and metastatic lymph nodes: a predictor of EGFR-TKI therapy response in non-small cell lung cancer.
- Author
-
Hu Y, Zhang Y, Lu Y, Xu Y, Xu J, Zhong H, Cheng L, and Zhong R
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Retrospective Studies, Lymph Nodes pathology, Lymph Nodes drug effects, Lymph Nodes metabolism, Adult, Aged, 80 and over, Treatment Outcome, Predictive Value of Tests, Mutation, Biomarkers, Tumor genetics, Biomarkers, Tumor biosynthesis, Biomarkers, Tumor metabolism, Biomarkers, Tumor analysis, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung metabolism, B7-H1 Antigen biosynthesis, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen metabolism, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Lung Neoplasms genetics, Lung Neoplasms metabolism, ErbB Receptors biosynthesis, ErbB Receptors genetics, ErbB Receptors metabolism, ErbB Receptors antagonists & inhibitors, Protein Kinase Inhibitors therapeutic use, Lymphatic Metastasis
- Abstract
Background: There is inconclusive evidence to suggest that the expression of programmed cell death ligand 1 (PD-L1) is a putative predictor of response to EGFR-TKI therapy in advanced EGFR-mutant non-small cell lung cancer (NSCLC). We evaluated the heterogeneity in PD-L1 expression in the primary lung site and metastatic lymph nodes to analyze the association between PD-L1 expression and response for patients treated with EGFR-TKI., Methods: This study reviewed 184 advanced NSCLC patients with EGFR mutations who received first-generation EGFR-TKI as first-line treatment from 2020 to 2021 at Shanghai Chest Hospital. The patients were divided into the primary lung site group (n = 100) and the metastatic lymph nodes group (n = 84) according to the biopsy site. The patients in each group were divided into TPS < 1%, TPS 1-49%, and TPS ≥ 50% groups according to PD-L1 expression., Results: The median PFS was 7 (95% CI: 5.7-8.3) months, and the median OS was 26 (95% CI: 23.5-28.5) months for all patients. No correlation existed between PFS or OS and PD-L1 expression. The median PFS in the primary lung site group was 11 months (95% CI: 9.6-12.4) in the TPS < 1% group, 8 months (95% CI: 6.6-9.4) in TPS 1-49% group, and 4 months (95% CI: 3.2-4.8) in TPS ≥ 50% group, with statistically significant differences (p = 0.000). The median OS of the TPS < 1% group and TPS ≥ 50% group showed a statistically significant difference (p = 0.008) in the primary lung site group. In contrast, PD-L1 expression in the lymph nodes of EGFR-mutant patients was unrelated to PFS or OS after EGFR-TKI therapy., Conclusion: PD-L1 expression from the primary lung site might predict clinical benefit from EGFR-TKI, whereas PD-L1 from metastatic lymph nodes did not., Trial Registration: This retrospective study was approved by the Ethics Committee of Shanghai Chest Hospital (ID: IS23060) and performed following the Helsinki Declaration of 1964 (revised 2008)., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF